Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on April 8, 2026. The filing discloses a strategic clinical collaboration agreement entered into on the same date with AstraZeneca plc.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate event under Item 8.01 (Other Events).
Material Changes and Strategic Developments
- Clinical Collaboration: IDEAYA Biosciences entered into an agreement with AstraZeneca to evaluate IDE849, an investigational DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca's Imfinzi (durvalumab).
- Target Indication: The study targets extensive-stage small cell lung cancer (SCLC).
- Roles: IDEAYA will sponsor the clinical combination study, while AstraZeneca will supply the Imfinzi drug.
- Broader Program: IDEAYA is advancing a multi-site global Phase 1 trial for IDE849 across DLL3 upregulated solid tumors, including SCLC, neuroendocrine carcinomas (NECs), neuroendocrine tumors (NETs), and melanoma.
Outlook, Risks, and Management Commentary
Management highlights DLL3 as a promising therapeutic target due to its upregulation in multiple solid tumors and limited expression in normal tissues. The filing includes standard forward-looking statements regarding the potential benefits of the therapeutics and the timing of clinical updates.
Key Risks Disclosed:
- Uncertainties inherent in early-stage clinical development.
- Risk that preclinical or clinical trial results may not predict future outcomes.
- Potential failure to enroll patients or proceed with trials as planned.
- Risk that product candidates may not demonstrate sufficient safety or efficacy.
- Reliance on third-party collaborators for drug supply and execution.
Investor Verification Checklist
- Verify the specific terms of the collaboration agreement, including any potential milestone payments or equity arrangements not detailed in this summary.
- Review the Company's most recent Form 10-K (dated February 17, 2026) for current cash runway and burn rate to assess funding sufficiency for the new global trials.
- Monitor enrollment progress for the Phase 1 IDE849 trial across the specified global regions.
- Track regulatory updates regarding the combination therapy of IDE849 and Imfinzi.